DESIGN THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
DESIGN THERAPEUTICS INC. - More news...
DESIGN THERAPEUTICS INC. - More news...
- Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
- Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
- Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
- Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
- Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
- Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
- Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
- Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
- Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
- Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
- Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
- Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
- Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
- Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
- Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
- Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
- Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
- Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
- Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
- Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
- Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
- Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
- Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
- Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
- Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
- Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
- Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
- Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
- Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
- Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
